Researchers have developed an experimental technique that uses magnetic nanoparticles to stimulate deep brain structures involved in Parkinson’s disease without permanently implanted electrodes. In a preclinical study, the approach significantly improved movement deficits in mice with Parkinson’s-like symptoms, offering a potential alternative to conventional deep brain stimulation (DBS).
The international research team, led by scientists from Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), RWTH Aachen University and the universities of Maastricht and Leuven, published its findings in Advanced Science.
Magnetic stimulation without implanted electrodes
Parkinson’s disease is caused by the progressive loss of dopamine-producing nerve cells, disrupting the brain circuits responsible for movement. While deep brain stimulation can reduce symptoms in selected patients, the treatment requires electrodes to be surgically implanted in the brain and connected to a pulse generator placed under the collarbone. The invasive nature of the procedure means that not all patients are eligible or willing to undergo treatment.
The newly developed method aims to achieve a similar therapeutic effect using magnetic nanoplatelets instead of electrical stimulation. Researchers injected specially engineered magnetic particles into the subthalamic nucleus (STN), a brain region that is also the primary target of conventional DBS.
Unlike implanted electrodes, the nanoparticles respond to externally applied magnetic fields by generating tiny mechanical forces. These forces slightly deform nearby cell membranes, activating naturally occurring mechanosensitive ion channels. The resulting ion flow alters neuronal activity without requiring direct electrical stimulation.
Improved motor function
To evaluate the approach, the researchers used a mouse model in which the same type of dopamine-producing neurons affected in Parkinson’s disease had been damaged, producing movement impairments comparable to those seen in patients.
Using stereotactic neurosurgical techniques, the team precisely delivered the magnetic nanoparticles into the animals’ subthalamic nucleus. After exposure to an external magnetic field, the treated mice showed a significant improvement in motor performance.According to the researchers, the therapeutic effect was comparable to the level expected from conventional deep brain stimulation.
The nanoparticles remained in the brain throughout a follow-up period of several months without signs of inflammation, suggesting they were well tolerated in the animal model. Although encouraging, the findings remain limited to preclinical research and further studies will be required to evaluate safety, long-term effects and effectiveness in humans.
Less invasive treatment
The research team is now investigating ways to make the technique even less invasive. One avenue under exploration is developing magnetic nanoparticles capable of crossing the blood-brain barrier after being administered through the bloodstream, eliminating the need for direct brain injections. Researchers are also studying wearable devices that could generate the required magnetic fields outside the body. Potential concepts include lightweight headbands that patients could use independently to activate the nanoparticles after treatment.
Such developments remain several years away from potential clinical application. However, the scientists believe the technology could eventually provide a more flexible and potentially less costly alternative to implanted brain pacemakers. Because stimulation is controlled by adjusting the external magnetic field rather than surgically implanted hardware, treatment parameters could potentially be modified more precisely over time.
Beyond its therapeutic potential, the technology may also provide neuroscientists with a new research tool for investigating how small mechanical forces influence neuronal activity and brain function. The authors suggest this could contribute to a broader understanding of neurological disorders while supporting the development of future non-electrical neuromodulation strategies.
New treatment strategy
Last year researchers at Northwestern Medicine identified a potential strategy to improve Parkinson’s disease treatment by targeting abnormal learning processes in the brain that develop during long-term levodopa therapy. The study suggested these disrupted mechanisms in the striatum contribute to levodopa-induced dyskinesia, the involuntary movements that often occur in advanced stages of the disease. In experiments using a Parkinson’s mouse model, the researchers found that altered interactions between dopamine and acetylcholine drive these abnormal learning processes.
By genetically and pharmacologically blocking specific acetylcholine receptors, they were able to reduce the severity of dyskinesias. The findings point to a possible way of extending the effectiveness of levodopa while limiting its side effects. Although the results are based on preclinical research, the approach could eventually provide a less invasive alternative to reducing medication doses or resorting to deep brain stimulation.
